Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 16:9:6475-82.
doi: 10.2147/DDDT.S40694. eCollection 2015.

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes

Paolo Ricchi  1 , Maria Marsella  2
Affiliations
Review

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes

Paolo Ricchi et al. Drug Des Devel Ther. .

Abstract

It has been clearly shown that iron overload adds progressively significant morbidity and mortality in patients with non-transfusion-dependent thalassemia (NTDT). The lack of physiological mechanisms to eliminate the excess of iron requires effective iron chelation therapy. The reduced compliance to deferoxamine and the risk of severe hematological adverse events during deferiprone treatment have limited the use of both these drugs to correct iron imbalance in NTDT. According to the principles of evidence-based medicine, following the demonstration of the effectiveness and the safety of deferasirox (Exjade(®)) in a prospective, randomized, controlled trial, deferasirox was approved by the US Food and Drug Administration in May 2013 for the treatment of iron overload associated with NTDT. This review, assessing the available scientific literature, will focus on the profile of DFX in the treatment of non-transfusional hemosiderosis in patients with NTDT.

Keywords: deferasirox; iron overload; non-transfusion-dependent thalassemia; profile.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 2012;26S:S7–S1. - PubMed
    1. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3–S6. - PubMed
    1. Ricchi P, Filosa A, Maggio A, Fucharoen S. Non-transfusion-dependent thalassemia: a complex mix of genetic entities yet to be fully discovered. Biomed Res Int. 2015;2015:161434. - PMC - PubMed
    1. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833–844. - PMC - PubMed
    1. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in b-thalassemia. Haematologica. 2007;92:583–588. - PubMed